Levels of endocannabinoid metabolizing enzymes are not related with BDNF levels in patients with schizophrenia: a case-controlled study

References

• Muller-Vahl KR, Emrich HM. Cannabis and schizophrenia: towards a cannabinoid hypothesis of schizophrenia. Expert Rev Neurother. 2008;8(7):1037–1048. Epub 2008/07/02. doi:10.1586/14737175.8.7.1037. PubMed PMID: 18590475.
   PubMedGoogle Scholar
• Leweke FM, Mueller JK, Lange B, et al. Therapeutic potential of cannabinoids in psychosis. Biol Psychiatry. 2016;79(7):604–612. doi: 10.1016/j.biopsych.2015.11.018
   Web of Science ®Google Scholar
• Appiah-Kusi E, Leyden E, Parmar S, et al. Abnormalities in neuroendocrine stress response in psychosis: the role of endocannabinoids. Psychol Med. 2016;46(1):27–45. doi: 10.1017/S0033291715001786
   Web of Science ®Google Scholar
• Desarnaud F, Cadas H, Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes identification and partial characterization. J Biol Chem. 1995;270(11):6030–6035. doi: 10.1074/jbc.270.11.6030
   Web of Science ®Google Scholar
• Beltramo M, Stella N, Calignano A, et al. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 1997;277(5329):1094–1097. doi: 10.1126/science.277.5329.1094
   PubMed Web of Science ®Google Scholar
• Martinotti G, Di Iorio G, Marini S, et al. Nerve growth factor and brain-derived neurotrophic factor concentrations in schizophrenia: a review. J Biol Regul Homeost Agents. 2012;26(3):347.
   PubMed Web of Science ®Google Scholar
• Qin XY, Wu HT, Cao C, et al. A meta-analysis of peripheral blood nerve growth factor levels in patients with schizophrenia. Mol Psychiatry. 2017;22(9):1306–1312. Epub 2017/01/11. doi:10.1038/mp.2016.235. PubMed PMID: 28070123.
   Web of Science ®Google Scholar
• Butovsky E, Juknat A, Goncharov I, et al. In vivo up-regulation of brain-derived neurotrophic factor in specific brain areas by chronic exposure to Δ9-tetrahydrocannabinol. J Neurochem. 2005;93(4):802–811. doi: 10.1111/j.1471-4159.2005.03074.x
   Web of Science ®Google Scholar
• Maj PF, Collu M, Fadda P, et al. Long-term reduction of brain-derived neurotrophic factor levels and signaling impairment following prenatal treatment with the cannabinoid receptor 1 receptor agonist (R)-(+)-[2,3-dihydro-5-methyl-3-(4-morpholinyl-methyl) pyrrolo[1,2,3-de]-1,4-benzoxazin-6-yl]-1- naphthalenylmethanone. Eur J Neurosci. 2007;25(11):3305–3311. Epub 2007/06/08. doi:10.1111/j.1460-9568.2007.05565.x. PubMed PMID: 17552998.
   Web of Science ®Google Scholar
• D’Souza DC, Pittman B, Perry E, et al. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacol. 2009;202(4):569–578. doi: 10.1007/s00213-008-1333-2
   Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276. doi: 10.1093/schbul/13.2.261
   PubMed Web of Science ®Google Scholar
• Kostakoğlu E, Batur S, Tiryaki A, et al. Pozitif ve Negatif Sendrom Ölçeğinin (PANSS) Türkçe uyarlamasının geçerlik ve güvenilirliği. Türk Psikoloji Dergisi 1999;14:23–32.
   Web of Science ®Google Scholar
• Guy W. CGI clinical global impressions. ECDEU assessment manual for psychopharmacology. Rockville (MD): National Institute of Mental Health; 1976. p. 217–221.
   Google Scholar
• Leucht S, Samara M, Heres S, et al. Dose equivalents for second-generation antipsychotic drugs: the classical mean dose method. Schizophr Bull. 2015;41(6):1397–1402. doi: 10.1093/schbul/sbv037
   PubMed Web of Science ®Google Scholar
• De Marchi N, De Petrocellis L, Orlando P, et al. Endocannabinoid signalling in the blood of patients with schizophrenia. Lipids Health Dis. 2003;2(1):5. doi: 10.1186/1476-511X-2-5
   PubMedGoogle Scholar
• Bioque M, Garcia-Bueno B, Macdowell KS, et al. Peripheral endocannabinoid system dysregulation in first-episode psychosis. Neuropsychopharmacol. 2013;38(13):2568–2577. Epub 2013/07/05. doi:10.1038/npp.2013.165. PubMed PMID: 23822951; PubMed Central PMCID: PMCPMC3828529.
   PubMed Web of Science ®Google Scholar
• Alhouayek M, Masquelier J, Muccioli GG. Controlling 2-arachidonoylglycerol metabolism as an anti-inflammatory strategy. Drug Discov Today. 2014;19(3):295–304. doi: 10.1016/j.drudis.2013.07.009
   PubMed Web of Science ®Google Scholar
• Leza JC, García-Bueno B, Bioque M, et al. Inflammation in schizophrenia: a question of balance. Neurosci Biobehav Rev. 2015;55:612–626. doi: 10.1016/j.neubiorev.2015.05.014
   PubMed Web of Science ®Google Scholar
• Olah A, Ambrus L, Nicolussi S, et al. Inhibition of fatty acid amide hydrolase exerts cutaneous anti-inflammatory effects both in vitro and in vivo. Exp Dermatol. 2016;25(4):328–330. Epub 2016/01/08. doi:10.1111/exd.12930. PubMed PMID: 26738935.
   Web of Science ®Google Scholar
• Lodola A, Castelli R, Mor M, et al. Fatty acid amide hydrolase inhibitors: a patent review (2009–2014). Expert Opin Ther Pat. 2015;25(11):1247–1266.
   PubMed Web of Science ®Google Scholar
• Hernangómez M, Mestre L, Correa FG, et al. CD200-CD200R1 interaction contributes to neuroprotective effects of anandamide on experimentally induced inflammation. Glia. 2012;60(9):1437–1450. doi: 10.1002/glia.22366
   PubMed Web of Science ®Google Scholar
• Leweke FM, Giuffrida A, Wurster U, et al. Elevated endogenous cannabinoids in schizophrenia. Neuroreport. 1999;10(8):1665–1669. doi: 10.1097/00001756-199906030-00008
   PubMed Web of Science ®Google Scholar
• Leweke FM, Piomelli D, Pahlisch F, et al. Cannabidiol enhances anandamide signaling and alleviates psychotic symptoms of schizophrenia. Transl Psychiatry. 2012;2:e94. Epub 2012/07/27. doi:10.1038/tp.2012.15. PubMed PMID: 22832859; PubMed Central PMCID: PMCPMC3316151.
   PubMed Web of Science ®Google Scholar
• Giuffrida A, Parsons L, Kerr T, et al. Dopamine activation of endogenous cannabinoid signaling in dorsal striatum. Nat Neurosci. 1999;2(4):358–363. doi: 10.1038/7268
   PubMed Web of Science ®Google Scholar
• Emrich HM, Leweke FM, Schneider U. Towards a cannabinoid hypothesis of schizophrenia: cognitive impairments due to dysregulation of the endogenous cannabinoid system. Pharmacol Biochem Be. 1997;56(4):803–807. Epub 1997/04/01. PubMed PMID: 9130308. doi: 10.1016/S0091-3057(96)00426-1
   PubMed Web of Science ®Google Scholar
• Leweke FM, Schneider U, Thies M, et al. Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacol. 1999;142(3):230–235. Epub 1999/04/20. PubMed PMID: 10208314. doi: 10.1007/s002130050884
   PubMed Web of Science ®Google Scholar
• Giuffrida A, Leweke FM, Gerth CW, et al. Cerebrospinal anandamide levels are elevated in acute schizophrenia and are inversely correlated with psychotic symptoms. Neuropsychopharmacol. 2004;29(11):2108–2114. Epub 2004/09/09. doi:10.1038/sj.npp.1300558. PubMed PMID: 15354183.
   PubMed Web of Science ®Google Scholar
• Wolf SA, Tauber S, Ullrich O. CNS immune surveillance and neuroinflammation: endocannabinoids keep control. Curr Pharm Des. 2008;14(23):2266–2278. Epub 2008/09/11. PubMed PMID: 18781977. doi: 10.2174/138161208785740090
   Web of Science ®Google Scholar
• Zoppi S, Perez Nievas BG, Madrigal JL, et al. Regulatory role of cannabinoid receptor 1 in stress-induced excitotoxicity and neuroinflammation. Neuropsychopharmacol. 2011;36(4):805–818. Epub 2010/12/15. doi:10.1038/npp.2010.214. PubMed PMID: 21150911; PubMed Central PMCID: PMCPMC3055736.
   PubMed Web of Science ®Google Scholar
• Giuffrida A, Seillier A. New insights on endocannabinoid transmission in psychomotor disorders. Prog Neuropsychopharmacol Biol Psychiatry. 2012;38(1):51–58. Epub 2012/04/24. doi:10.1016/j.pnpbp.2012.04.002. PubMed PMID: 22521335; PubMed Central PMCID: PMCPMC3389227.
   Web of Science ®Google Scholar
• Hwang J, Adamson C, Butler D, et al. Enhancement of endocannabinoid signaling by fatty acid amide hydrolase inhibition: a neuroprotective therapeutic modality. Life Sci. 2010;86(15–16):615–623. Epub 2009/06/17. doi:10.1016/j.lfs.2009.06.003. PubMed PMID: 19527737; PubMed Central PMCID: PMCPMC2848893.
   PubMed Web of Science ®Google Scholar